Full Press Release Details
NASDAQ: PBMD, ASX: PRR
JANUARY 2017 CORPORATE
Notice: Forward Looking Statements
the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or
clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please refer to
the Company s website and/or the
Company s filings to the ASX and SEC for further information.
The views expressed in this presentation contain information derived from publicly available sources that have
not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions
which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed s control. Important factors that could
cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed s current
intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima
BioMed. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.
Biopharmaceutical company
developing novel immunotherapeutic products for cancer and autoimmune diseases
understanding of the LAG-3 immune control mechanism:
Fr d ric Triebel (Prima s CSO & CMO) discovered LAG-3 in 1990 and is a leading LAG-3 thought leader
LAG-3 plays a vital role in the regulation of T cell immune response and is one of
the four primary checkpoint inhibitor targets
Lead product candidate, IMP321 is in ongoing clinical
development (Phase IIb + I studies)
IMP321 is an antigen presenting cell (APC) activator and fusion protein
and is a soluble dimeric form of LAG-3
partnerships including, GSK and Novartis
Poised for meaningful news and data flow in 2017
Directors & Officers
Lucy Turnbull, AO, Non-executive Chairman
Businesswoman and philanthropist; previously on the
boards of the Cancer Institute of NSW and Australian Technology Park
Albert Wong, Non-executive Deputy Chairman
Australian investment banker; several
Marc Voigt, Executive Director & Chief Executive Officer
17+ years in leading positions in finance, venture capital and biotech industry
Prof. Fr d ric Triebel, MD PhD, CSO & CMO/Immutep S.A.S.
Clinical haematologist, and PhD in immunology (Paris University) and successfully developed several research programs in
immunogenetics and immunotherapy, leading to 144 publications and 16 patents
Pete A Meyers, Non-executive Director
CFO of Motif Bio; previous Co-Head of Global Health Care Investment Banking at Deutsche Bank
Howard, PhD, Non-executive Director
Scientist entrepreneur; previously
CEO of Maxygen & Oakbio, positions at NIH, DNAX, Affymax
Deanne Miller, General Counsel, Company
Lawyer; previous positions at RBC Investor Services, Westpac, Macquarie and ASIC
LAG-3 As a Therapeutic Target
LAG-3 is widely expressed on tumor infiltrating lymphocytes (TILs) and cytotoxic T cells ? Prime target for an immune checkpoint blocker
Functionally similar to CTLA-4 (targeted by Yervoy ) and PD-1 (Keytruda )
LAG-3/ MHC class II interaction Positive
Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications
LAG-3 is an Important I-O Target
In 1990 Prof. Triebel discovered LAG-3 and subsequently also discovered the LAG-3 ligand MHC class II
and its importance in the immune system
LAG-3 is the subject of
363 PubMed publications:
- 102 publications of LAG-3 in immune system
- 141 publications of LAG-3 in context of I-O
- 16 publications of promising
pre-clinical data on LAG-3 and cancer immunotherapy1
Multiple companies developing anti-LAG-3 mAb in pre-clinical
and clinical studies (including Prima BioMed and partners)
LAG-3 s potential synergistic function with PD-1 and PD-L1 is very promising1:
Simultaneous blockade of LAG-3 and
PD-1 synergistically enhance T-cell activity and antitumor immunity in mouse models 2
1 He Y. et al. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci.
2 Woo et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012
Growing Interest in LAG-3
Overall understanding and appreciation of the importance of LAG-3 s role in the
immune system continues to grow
Trajectory of the PubMed articles on LAG-3 cancer is similar to that of PD-1
and Cancer Publications
19992003200720112015
Lag-3 CancerPd-1 Cancer
8 PubMed searches of Lag-3 Cancer and Pd-1 Cancer from January 1, 1999 December 6, 2016
Preclinical Phase IPhase IIaPhase IIbWW Prima
Metastatic Breast (ex China: Eddingpharm)
Cancer Phase IIb trial began Oct 2015
MOA: APC activator following first-line chemotherapy
Concept (ex China: Eddingpharm)
Study in Metastatic Phase I
trial began Jan 2016
Melanoma MOA: APC activator +
PD-1 checkpoint inhibitor (i.e.
trial began Jan 2015
Phase I trial began Aug 2015
MOA: LAG-3 antagonist antibody
Diseases MOA: LAG-3 agonist antibody
Autologous Dendritic Cell Therapy
9 Ovarian Cancer (ex Israel: Neopharm)
Phase IIb completed (CAN-003)
Soluble recombinant form of LAG-3
Human fusion protein
Dimeric, very stable, high
Antigen presenting cell (APC) activator
Soluble dimeric recombinant form of LAG-3Ig (fusion protein)
Highly efficacious in multiple
animal models of cancer and infectious disease
non-immunogenic and efficacious in humans
12 (Clin Cancer Res. 2008 Jun 1;14(11):3545-54)
IMP321 Potential Applications
combination therapy strategies:
Chemo-immunotherapy in various cancer indications Combination therapy